CYT 007 TNFQb

Drug Profile

CYT 007 TNFQb

Alternative Names: CYT007-TNFQb

Latest Information Update: 19 Sep 2008

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Class Antipsoriatics; Antirheumatics; Vaccines
  • Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2008 Discontinued - Phase-I/II for Psoriasis in Germany (Parenteral)
  • 19 Sep 2008 Discontinued - Preclinical for Rheumatoid arthritis in Switzerland (Parenteral)
  • 12 Jun 2007 Clinical data added to the adverse events and Skin Disorders immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top